revenue
9450–9600 $million
FY 2025
official guidance
| Revenue | $1.5B |
|---|---|
| Operating income | $100.4M |
| Net income | $94.8M |
| Free cash flow | $127.5M |
| Operating margin | 6.7% |
| Net margin | 6.4% |
| Return on equity | 23.5% |
| Period | TTM 2026-06-27 |
OpenFilings analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
High-quality growth and raised guidance are offset by unresolved Librela adoption and competitive-launch risk.
Latest call · Q3 2026Zoetis delivered a strong Q2:
revenue was $2.5 billion, up 8% organically, adjusted net income rose 10%, and management raised 2025 organic revenue-growth guidance to 6.5%-8%. The core Simparica and dermatology franchises remain resilient, but Librela fell 16% in the U.S. and the expected Q4 dermatology launch creates meaningful second-half risk; the call supports a hold rather than a fresh buy until those issues improve.
Q3-Q4 comparisons become difficult, with U.S. companion-animal revenue having grown 18% in Q3 2024.
A competing dermatology product is expected to launch in Q4, with promotional intensity and label scope still uncertain.
Librela third-party studies are expected to begin reading out in Q4 2025 and continue into 2026; evidence will be important for restoring veterinarian recommendations.
Tariff treatment remains unclear, although management says currently enacted and announced tariffs are embedded in guidance and manageable.
Alternative channels represented about 22% of U.S. companion-animal revenue and grew 25%-30%, but retail stocking provided a potentially temporary benefit.
Simparica Trio remains a strong growth engine: triple-combination share in U.S. veterinary practices reached 45%, and management expects the category to double by the end of 2028.
Key dermatology grew 11% in Q2 and continues to benefit from under-treated or untreated medicalized dogs, compliance, and differentiated Apoquel Chew and Cytopoint offerings.
Management expects a major-market approval every year for the next several years, including long-acting osteoarthritis products and potential renal, oncology, and cardiology opportunities.
Livestock growth has exceeded expectations for five consecutive quarters, adding diversification beyond companion animal franchises.
Competitive moat risk remains concentrated in parasiticide and dermatology launches; management's claims of stable patient share need to be tested through the upcoming Q4 launch cycle.
Librela declined 16% in U.S. sales and 7% globally in Q2; management acknowledged adoption and veterinarian recommendation have materially lagged expectations.
Management could not provide a timing target for Librela's return to year-over-year growth, relying instead on education and future third-party data.
International Librela growth slowed to 1%, with social-media headwinds spreading into English-speaking markets.
The raised full-year outlook still assumes launch-related competitive headwinds in the second half, and management described timing, promotional intensity, and competitor labels as uncertain.
Reported adjusted gross margin of 73.7% benefited from FX and the MFA divestiture; manufacturing-cost improvement is expected, but underlying margin progression remains partly timing-dependent.
revenue
9450–9600 $million
FY 2025
official guidance
revenue growth
6.5–8 pct
FY 2025
official guidance
adjusted eps
6.3–6.4 $per share
FY 2025
official guidance
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
SONOS, INC.
SONOS, INC.
SONOS, INC.
SONOS, INC.
SONOS, INC.
SONOS, INC.